Biologics Regulatory Affairs Services — Global Support
From early-stage development to global market access, we help biologic products meet country-specific requirements with clarity and confidence.

Services We Offer
Biologics demand a different level of regulatory attention. From product characterization and comparability studies to post-market obligations, each step is bound by region-specific protocols. At Artixio, we work closely with companies developing monoclonal antibodies, vaccines, cell and gene therapies, or biosimilars, offering regulatory guidance shaped by science, precision, and country requirements.
Whether you’re preparing for FDA’s BLA pathway, EMA’s centralized procedure, or gaining acceptance in APAC, MENA, or LATAM regions, we help you align your product with the local authorities’ expectations — without slowing down your launch timelines.
Regulatory Affairs Lifecycle for Biologics
Pre-Development Advisory
Identify target market-specific requirements early
Product Characterization & Dossier Planning
Align studies, comparability, and data with regional needs
Regulatory Submissions
Prepare CTD, eCTD or other required formats
Authority Communication & Response Management
Handle queries, deficiencies, and updates promptly
Market Authorization & Launch Readiness
Support labeling, packaging, and final review steps
Post-Market Compliance & Reporting
Safety data, variations, renewals, and lifecycle tracking
Why Artixio for Biologics Regulatory Affairs

15–35 years of cross-functional experience in biologics regulation, CMC strategy, and global submissions

Specialized teams for FDA, EMA, PMDA, and other regional pathways

Real-time coordination with CMC, clinical, and safety stakeholders

Documentation built from scientific evidence, not templates

Proven record in managing centralized, hybrid, and national procedures

Global delivery with local regulatory insight

Integrated support for both development-stage and commercial-stage biologics

Personalized communication and dedicated project ownership
FAQs
1. What is the difference between drug and biologic regulation globally?
Biologics are regulated through separate agencies or divisions within regulatory bodies due to their complexity, variability, and production methods. Requirements around characterization, stability, and comparability are far more detailed than for small molecules.
2. Does Artixio support gene therapies and cell-based products too?
Yes, we handle a wide range of biologics, including ATMPs (Advanced Therapy Medicinal Products) such as gene therapies, CAR-T cells, and stem cell-based treatments.
3. How does Artixio assist with biosimilar registration across countries?
We help with data bridging, justification strategies, and comparability assessments for biosimilars across US, EU, and other major markets. We also support local requirements in emerging markets.
4. Can you manage regulatory submissions across multiple countries at once?
Yes, our team can coordinate simultaneous submissions through a unified strategy while aligning with each authority’s documentation preferences and timelines.
5. What kind of post-approval support do you offer for biologics?
We manage variations, renewals, safety reports, and manufacturing changes across different health authorities so your approvals remain active and compliant.
Still Have Questions ?
Get expert answers tailored to your needs.
Specialized Regulatory Affairs Services Across Multiple Industries
Expert Regulatory Services To Streamline Compliance

Regulatory Intelligence & Strategy

Medical & Technical Writing

Publishing & Submission

Product Registration

Investigation New Drug Application (IND)

New Drug Application (NDA)

Post Approval Lifecycle Maintenance

Artwork and Label Review

Ad Promo Review
Regulatory Affairs Across Multiple Countries

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

Europe

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea
Insights from Artixio - Tips & Articles

In Vitro Diagnostics: Meaning,
The term “in vitro” is a Latin word that means “in glass”. Thus, from...
June 20, 2025

IVD Medical Devices Registration
The in vitro diagnostic in India is regulated by the Central Drugs Standard Control...
June 17, 2025

Pharma Manufacturing Booms in
Once overlooked pharma hub in Mexico's Hidalgo region has gained importance with global market...
June 18, 2025